XNCR Stock Forecast 2025-2026
Distance to XNCR Price Targets
XNCR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Xencor (XNCR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on XNCR and similar high-potential opportunities.
Latest XNCR Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, XNCR has a bullish consensus with a median price target of $30.50 (ranging from $22.00 to $40.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $11.81, the median forecast implies a 158.3% upside. This outlook is supported by 10 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Sean McCutcheon at Raymond James, projecting a 238.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XNCR Analyst Ratings
XNCR Price Target Range
Latest XNCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XNCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $33.00 |
| Dec 12, 2024 | Wells Fargo | Eva Fortea Verdejo | Overweight | Initiates | $37.00 |
| Dec 2, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Upgrade | $30.00 |
| Nov 8, 2024 | BMO Capital | Etzer Darout | Outperform | Reiterates | $34.00 |
| Nov 7, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $28.00 |
| Sep 26, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $34.00 |
| Aug 6, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $31.00 |
| Aug 6, 2024 | BMO Capital | Etzer Darout | Outperform | Reiterates | $32.00 |
| Jul 31, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $27.00 |
| Jun 14, 2024 | Raymond James | Sean McCutcheon | Strong Buy | Maintains | $40.00 |
| Jun 14, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $32.00 |
| Jun 14, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $31.00 |
| May 10, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $36.00 |
| Apr 16, 2024 | BTIG | Kaveri Pohlman | Buy | Maintains | $38.00 |
| Feb 28, 2024 | Piper Sandler | Edward Tenthoff | Neutral | Downgrade | $24.00 |
| Feb 28, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $34.00 |
| Feb 28, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $34.00 |
| Feb 28, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $32.00 |
| Jan 22, 2024 | Mizuho | Mara Goldstein | Buy | Maintains | $50.00 |
| Nov 8, 2023 | Wedbush | David Nierengarten | Outperform | Maintains | $36.00 |
Xencor Inc. (XNCR) Competitors
The following stocks are similar to Xencor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xencor Inc. (XNCR) Financial Data
Xencor Inc. has a market capitalization of $912.48M with a P/E ratio of -3.1x. The company generates $110.49M in trailing twelve-month revenue with a -210.5% profit margin.
Revenue growth is +37.4% quarter-over-quarter, while maintaining an operating margin of +9.1% and return on equity of -35.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Xencor Inc. (XNCR) Business Model
About Xencor Inc.
Develops engineered monoclonal antibodies for therapies.
Xencor Inc. operates by utilizing its proprietary XmAb technology to create engineered monoclonal antibodies aimed at treating cancer and autoimmune disorders. The company collaborates with various industry leaders to advance and commercialize its drug candidates, generating revenue through partnerships and potential product sales.
Based in California, Xencor emphasizes scientific excellence and innovation in biotechnology, positioning itself as a key player in enhancing treatment options for complex diseases. Its focus on improving therapeutic profiles and patient outcomes highlights its commitment to advancing healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
250
CEO
Dr. Bassil I. Dahiyat Ph.D.
Country
United States
IPO Year
2013
Website
www.xencor.comXencor Inc. (XNCR) Latest News & Analysis
Xencor, Inc. appointed Todd Simpson to its board of directors. Simpson has 40+ years of CFO experience, recently serving at Seagen Inc. through its 2023 acquisition.
Todd Simpson's appointment brings extensive financial expertise, potentially enhancing Xencor's strategic direction and investor confidence, especially in its development pipeline.
Xencor, Inc. (NASDAQ:XNCR) reported its Q4 and full-year 2024 financial results and is rebalancing its pipeline to focus on XmAb® drug candidates for cancer and autoimmune diseases.
Xencor's strategic pipeline rebalancing highlights a focus on its engineered antibodies, which could enhance growth prospects and attract investor interest in its clinical developments.
Xencor (XNCR) reported a quarterly loss of $0.62 per share, better than the Zacks Consensus Estimate of $0.83, but worse than a loss of $0.31 per share from the previous year.
Xencor's smaller-than-expected loss indicates potential operational improvements, which may boost investor confidence and impact future stock performance positively.
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
1 month agoNeuberger Berman's co-CIOs report a shift in the stock market dynamic as investors begin to move past concerns about inflation.
Shifting focus from inflation concerns may lead to increased market stability and investment opportunities, potentially boosting stock valuations and encouraging risk-taking.
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
1 month agoXencor (XNCR) is now technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates upward, indicating a potential trend reversal.
Xencor (XNCR) being oversold signals reduced selling pressure, while higher earnings estimates suggest possible price recovery, making it an attractive opportunity for investors.
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
2 months agoXencor (XNCR) is currently oversold, indicating potential exhaustion of selling pressure. Analysts are raising earnings estimates, which may signal a trend reversal for the stock.
Xencor's oversold status suggests potential for price recovery, while raised earnings estimates from analysts indicate improved financial outlook, signaling a possible buying opportunity.
Frequently Asked Questions About XNCR Stock
What is Xencor Inc.'s (XNCR) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Xencor Inc. (XNCR) has a median price target of $30.50. The highest price target is $40.00 and the lowest is $22.00.
Is XNCR stock a good investment in 2025?
According to current analyst ratings, XNCR has 10 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $11.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XNCR stock?
Wall Street analysts predict XNCR stock could reach $30.50 in the next 12 months. This represents a 158.3% increase from the current price of $11.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xencor Inc.'s business model?
Xencor Inc. operates by utilizing its proprietary XmAb technology to create engineered monoclonal antibodies aimed at treating cancer and autoimmune disorders. The company collaborates with various industry leaders to advance and commercialize its drug candidates, generating revenue through partnerships and potential product sales.
What is the highest forecasted price for XNCR Xencor Inc.?
The highest price target for XNCR is $40.00 from Sean McCutcheon at Raymond James, which represents a 238.7% increase from the current price of $11.81.
What is the lowest forecasted price for XNCR Xencor Inc.?
The lowest price target for XNCR is $22.00 from at , which represents a 86.3% increase from the current price of $11.81.
What is the overall XNCR consensus from analysts for Xencor Inc.?
The overall analyst consensus for XNCR is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $30.50.
How accurate are XNCR stock price projections?
Stock price projections, including those for Xencor Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
